Upgrade to SI Premium - Free Trial

Cardiol Therapeutics (CRDL)

1.22 -0.03 (2.40%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/16/22)

Latest Headlines

Form 6-K Cardiol Therapeutics For: Jun 30 August 10, 2022 4:26 PM - SEC Filing Form 6-K Cardiol Therapeutics For: Aug 03 August 3, 2022 7:49 AM - SEC Filing Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis August 3, 2022 7:31 AM - StreetInsider Form 6-K Cardiol Therapeutics For: Jun 29 June 29, 2022 11:41 AM - SEC Filing Cardiol Therapeutics Reports Results of 2022 Annual General Meeting June 29, 2022 10:09 AM - StreetInsider Form 6-K Cardiol Therapeutics For: Jun 27 June 27, 2022 10:15 AM - SEC Filing Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT June 27, 2022 10:09 AM - StreetInsider Form 6-K Cardiol Therapeutics For: Jun 09 June 9, 2022 5:00 PM - SEC Filing Form SUPPL Cardiol Therapeutics June 9, 2022 4:33 PM - SEC Filing Cardiol Therapeutics (CRDL) Announces At-The-Market Equity Offering Program June 9, 2022 4:06 PM - StreetInsider Cardiol Therapeutics Announces At-The-Market Equity Offering Program June 9, 2022 4:06 PM - StreetInsider Form 6-K Cardiol Therapeutics For: May 24 May 24, 2022 2:29 PM - SEC Filing CEO Presenting on the Emerging Growth Conference on May 25 Register Now May 24, 2022 7:00 AM - Globe NewsWire Cardiol Therapeutics (CRDL) Appoints Teri Loxam and Chris Waddick to its Board May 19, 2022 7:30 AM - StreetInsider Form 6-K Cardiol Therapeutics For: May 19 May 19, 2022 7:30 AM - SEC Filing Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors May 19, 2022 7:29 AM - StreetInsider Cardiol Therapeutics (CRDL) Announces FDA IND Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis May 17, 2022 7:29 AM - StreetInsider Form 6-K Cardiol Therapeutics For: May 17 May 17, 2022 7:29 AM - SEC Filing Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis May 17, 2022 7:29 AM - StreetInsider Full Article List